Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-06-21
2011-06-21
Pak, Michael (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S142100
Reexamination Certificate
active
07964706
ABSTRACT:
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
REFERENCES:
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6177077 (2001-01-01), Tobinick
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6323329 (2001-11-01), Bullerdiek
patent: 6448233 (2002-09-01), Lefevre et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 7304034 (2007-12-01), Tracey et al.
patent: 2002/0009749 (2002-01-01), Ozaki et al.
patent: 2003/0017155 (2003-01-01), Tracey et al.
patent: 2003/0060410 (2003-03-01), Tracey et al.
patent: 2003/0113323 (2003-06-01), Tracey et al.
patent: 2003/0143194 (2003-07-01), Tracey et al.
patent: 2004/0053841 (2004-03-01), Tracey et al.
patent: 2004/0120953 (2004-06-01), Tracey et al.
patent: 2004/0141948 (2004-07-01), O'Keefe
patent: 2005/0118688 (2005-06-01), Freeze et al.
patent: 2005/0152903 (2005-07-01), Newman et al.
patent: 2006/0057679 (2006-03-01), O'Keefe et al.
patent: 2006/0099207 (2006-05-01), Wu et al.
patent: 1 079 849 (2002-01-01), None
patent: 62-166897 (1987-07-01), None
patent: 2003-096099 (2003-04-01), None
patent: WO-96-25493 (1996-08-01), None
patent: WO-97-23611 (1997-07-01), None
patent: WO-99-59609 (1999-11-01), None
patent: WO-00-47104 (2000-08-01), None
patent: WO-02-074337 (2002-09-01), None
patent: WO-02-092004 (2002-11-01), None
patent: WO-02-092004 (2002-11-01), None
patent: WO-2004-004763 (2004-01-01), None
patent: WO-2005-034952 (2005-04-01), None
patent: WO 2007/011606 (2007-01-01), None
patent: WO-2007-054090 (2007-05-01), None
patent: WO-2007-076200 (2007-07-01), None
patent: WO-2007-084253 (2007-07-01), None
Abaza, M. S., et al. “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin.”J.Protein Chem. (1992) 11: 433-44.
Abraham, E., et al. “HMG-1 as a Mediator of Acute Lung Inflammation.”J.Immunol. (2000) 165:2950-4.
An, L-L, and et al. “Targeting Different Isoforms of HMGB1 Leads to Different Beneficial Effects in Preclinical Models of Sepsis and Inflammatory Arthritis (Abstract and Presentation).” 94th Annual AAI Meeting. Miami Beach, FL, May 18-22, 2007. pp. 1-10.
Andersson, U., et al. “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes.”J.Exp.Med. (2000) 192: 565-70.
Ayer, L. M., et al. “Antibodies to HMG Proteins in Patients with Drug-Induced Autoimmunity ”Arthritis Rheum. (1994) 37:98 -103.
Banks, G. C., et al. “The HMG-I(Y) A.T-Hook Peptide Motif Confers DNA-Binding Specificity to a Structured Chimeric Protein.”J.Biol.Chem. (1999) 274: 16536-44.
Baxevanis, A. D., et al. “The HMG-1 Box Protein Family: Classification and Functional Relationships.”Nucleic Acids Res. (1995) 23: 1604-13.
Benjamini, E. “Antigenicity.”Immunology, A Short Course., 1991. 40.Wiley-LissNew York.
Bianchi, M. E., et al. “Specific Recognition of Cruciform DNA by Nuclear Protein HMG1.”Science(1989) 243: 1056-9.
Bianchi, M. E., et al. “The DNA Binding Site of HMG1 Protein is Composed of Two Similar Segments (HMG Boxes), both of which have Counterparts in Other Eukaryotic Regulatory Proteins.”EMBO J. (1992) 11: 1055-63.
Bustin, M. “Revised Nomenclature for High Mobility Group (HMG) Chromosomal Proteins.”Trends Biochem.Sci. (2001) 26: 152-3.
Bustin, M. “Regulation of DNA-Dependent Activities by the Functional Motifs of the High-Mobility-Group Chromosomal Proteins.”Mol.Cell.Biol. (1999) 19: 5237-46.
Bustin, M., et al. “Antigenic Determinants of High Mobility Group Chromosomal Proteins 1 and 2.”Biochemistry(1982) 21: 6773-7.
Bustin, M., et al “Immunological Relatedness of High Mobility Group Chromosomal Proteins from Calf Thymus.”J.Biol.Chem. (1978) 253: 1694-9.
Cattaneo, A., et al. “The Selection of Intracellular Antibodies.”Trends in biotechnology17.3 (1999): 115-21.
Chou, D. K., et al. “Identity of Nuclear High-Mobility-Group Protein, HMG-1, and Sulfoglucuronyl Carbohydratc-Binding Protcin, SBP-1, in Brain.”J.Ncurochcm. (2001) 77: 120-31.
Clackson, T., et al. “Making Antibody Fragments using Phage Display Libraries.”Nature(1991) 352: 624-8.
Colman, P. M. “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions.”Res.Immunol. (1994) 145: 33-6.
Coyle, A. J. “HMBG1—New Role for an Old Protein a Mediator of Inflammation and Autoimmune Disease (Presentation).” National Cancer Institute. Frederick, MD, Jun. 21, 2007. pp. 1-32.
Coyle, A. J., and et al. “HMBG1—New Role for an Old Protein a Mediator of Inflammation and Autoimmune Disease (Abstract and Presentation).” British Society of Biochemistry. Cambridge, UK, Aug. 8-10. pp. 1-32.
Czura, C. J., et al. “High Mobility Group Box-1 as a Therapeutic Target Downstream of Tumor Necrosis Factor.”J.Infect.Dis. (2003) 187 Suppl 2: S391-6.
Czura, C. J., et al. “Dual Roles for HMGB1: DNA Binding and Cytokine.”J.Endotoxin Res. (2001) 7: 315-21.
Daston, M. M., ct al. “Exprcssion of P30, a Protcin with Adhcsivc Properties, in Schwann Cclls and Neurons of the Developing and Regenerating Peripheral Nerve.”J.Cell Biol. (1991) 112: 1229-39.
Degryse, B., et al. “The High Mobility Group (HMG) Boxes of the Nuclear Protein HMG1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells.”J.Cell Biol. (2001) 152: 1197-206.
Dumitriu, I. E., et al. “Requirement of HMGB1 and RAGE for the Maturation of Human Plasmacytoid Dendritic Cells.”Eur.J.Immunol. (2005) 35: 2184-90.
Falciola, L., et al. “High Mobility Group 1 Protein is Not Stably Associated with the Chromosomes of Somatic Cclls.”J.Ccll Biol. (1997) 137: 19-26.
Freeman, B. D., et al. “The Role of Inflammation in Sepsis and Septic Shock: A Meta-Analysis of both Clinical and Preclinical Trials of Anti-Inflammatory Therapies.”Inflammation: Basic Principals and Clinical Correlates., 1999.pp. 965-975. Gallin, J.I.; Snyderman, R.eds., Lippincott, Williams & Wilkins Philadelphia.
GenBank. “Accession No. AAA64970, “HMG-1,” (1995) [Online] [Retrieved on Sep. 30, 2004]. Retrieved from the Intcrnct: <URL:Http://www.Ncbi.Nlm.Nih.gov/cntrcz/vicwcr.Fcgi?db=protcin&val=184251>.”
GenBank. “Accession No. AAB08987, “Non-Histone Chromatin Protein HMG1 [Homo sapiens],” (1996) [Online] [Retrieved on Mar. 21, 2006]. Retrieved from the Internet: <URL:Http://www.Ncbi.Nlm.Nih.gov/entrez/viewer.Fcgi?db=protein&val=1435197>.”
GcnBank. “Accession No. PO7155, “High Mobility Group Protcin 1 (HMG-1) (Amphotcrin) (Hcparin-Binding Protein p30),” (2004) [Online] [Retrieved on Mar. 21, 2006]. Retrieved f
An Ling-Ling
Coyle Anthony
Gao Changshou
Kiener Peter
Mao Su-Yau
Hamilton Brook Smith & Reynolds P.C.
MedImmune LLC
Pak Michael
LandOfFree
High affinity antibodies against HMGB1 and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High affinity antibodies against HMGB1 and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High affinity antibodies against HMGB1 and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630909